MedTrace Logo

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

NCT04335136 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2021-08-02

Study results available
· View outcomes & findings →

Summary

Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.

Conditions

Interventions

DRUG

RhACE2 APN01

Patients will be treated with APN01 intravenously twice daily (BID).

DRUG

Physiological saline solution

Patients will be treated with placebo intravenously twice daily (BID).

Sponsors & Collaborators

  • Apeiron Biologics

    lead INDUSTRY

Principal Investigators

  • Henning Bundgaard, MD. · Cap. Region's Unit of Inherited Cardiac Diseases, Faculty Health&Medical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2020-12-26
Completion
2020-12-26
FDA Drug
Yes

Countries

  • Austria
  • Denmark
  • Germany
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04335136 on ClinicalTrials.gov